EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating Duravyu for patients with diabetic macular edema, according to a press release.
“DME is a prevalent disease with a significant need for more durable treatments,” Jay S. Duker, MD, EyePoint’s president and CEO, said in the release. “The interim data from the VERONA trial demonstrates that after a single Duravyu 2.7 mg treatment there was a meaningful, early and maintained improvement in BCVA paired with strong anatomical improvement in retinal thickness,